Although research published in the 1990s revealed the therapeutic benefits of systemic copper depletion in animals implanted with VX2 carcinoma or experimental 9L-gliosarcoma [45,46] as models of brain cancer, whether excess copper mediates the upregulation of CcO activity to facilitate GBM progression remains unknown. This evidence concerns the gene RYR1 and glioblastoma.